MYCとp53の変異は,VEGFシグナル伝達により,前立腺がんにおける細胞毒性T細胞と免疫療法反応を抑制する
Katherine C Murphy1, Kelly D DeMarco1, Lin Zhou1
1University of Massachusetts Chan Medical School, Worcester, MA, United States.
Cancer research
|September 3, 2025
まとめ
前立腺がんにおけるVEGFシグナリングをターゲットにすることで,抗腫瘍免疫が再活性化されます. このアプローチは,腫瘍の成長を抑制し,CD8+ T細胞機能を強化することによって,攻撃的なカストレーション抵抗性前立腺がん (CRPC) のサブタイプにおける生存率を改善します.
科学分野:
- 腫瘍学
- 免疫学
- 遺伝学
背景:
- カストレーション抵抗性前立腺がん (CRPC) は,現在の治療法に抵抗することが多い.
- CRPCの遺伝的変化は,免疫反応と治療結果に影響を与える可能性があります.
- パーソナライズされた治療法の開発には これらの遺伝的要因を理解することが重要です
研究 の 目的:
- CRPCの遺伝的変異が腫瘍の免疫微環境にどのように影響するかを調査する.
- CRPCにおける免疫抑制メカニズムを特定する.
- これらのメカニズムを標的とした治療戦略を探求する.
主な方法:
- 特定の遺伝子変異 (MYC増幅,p53破壊) を有するCRPCマウスモデルを生成した.
- 免疫細胞の浸透と腫瘍の微小環境を分析した
- T細胞機能における VEGF-VEGFR2信号伝達の役割を調査した.
- 臨床前モデルにおけるVEGF- VEGFR2およびPD- L1の治療阻害を評価した.
主要な成果:
- MYCの増幅とCRPCのp53の破壊は,細胞毒性Tリンパ球の浸透を減少させ,予後を悪くした.
- MYCとp53の共同作用により,腫瘍のVEGF分泌が誘発され,VEGFR2経由でCD8+T細胞の移動と機能が抑制される.
- VEGF-VEGFR2阻害は免疫微環境を再構成し,腫瘍と転移の成長を抑制し,生存率を向上させた.
- VEGFR2阻害はPD- L1発現を増加させ,PD- L1免疫チェックポイント阻害剤の有効性を高めました.
結論:
- VEGFシグナルによるCRPCの免疫抑制の遺伝的メカニズムを特定した.
- VEGF-VEGFR2シグナリングをターゲットにすることで,攻撃的なCRPCの免疫回避を克服できます.
- この戦略は,抗腫瘍免疫を再活性化し,CRPCにおける免疫療法反応を改善する見込みです.
関連する概念動画
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:27Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:19Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
01:23Negative Regulator Molecules
35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K